Sunday , 19 January 2025
0

No products in the cart.

Worldwide News Worldwide News
0

No products in the cart.

Home Health Roche Expands Its Scope in Allogeneic Cell Therapy With $1B Poseida Therapeutics Acquisition
Health

Roche Expands Its Scope in Allogeneic Cell Therapy With $1B Poseida Therapeutics Acquisition

November 26, 20241 Mins read18 Views
Roche Expands Its Scope in Allogeneic Cell Therapy With $1B Poseida Therapeutics Acquisition

Roche is acquiring Poseida Therapeutics, a biotech developing allogeneic cell therapies for cancers and immunological indications. The two companies have been partners in hematological malignancies since 2022.

The post Roche Expands Its Scope in Allogeneic Cell Therapy With $1B Poseida Therapeutics Acquisition appeared first on MedCity News.

Previous post Trump's plan to impose 25% tariffs on Canadian and Mexican imports doesn't exempt oil

Leave a comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Related Articles

Health

AstraZeneca’s Calquence has expanded its FDA approval to include first-line treatment of...

ByJanuary 17, 2025

This interactive chart allows users to track public opinion on the Affordable...

ByJanuary 17, 2025
Health

By MIKE MAGEE In case you’ve missed it, sleep is all the...

ByJanuary 17, 2025
Health

Teladoc Health has joined Amazon’s Health Benefits Connector. Other companies offered through...

ByJanuary 17, 2025

Abous us

Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor. Aenean massa. Cum sociis natoque penatibus et magnis dis

Subscribe Now

    Subscribe to our mailing list to receives daily updates direct to your inbox!
    © Copyright 2022 Jellywp. All rights reserved powered by Jellywp.com